載脂蛋白A4(APOA4)多克隆抗體
Polyclonal Antibody to Apolipoprotein A4 (APOA4)
ApoA-IV; ApoAIV; Apo-A4
- 編號(hào)UPAB967Hu02
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 來(lái)源多抗制備
- 宿主兔
- 效價(jià)-
- Ig類型 IgG
- 純化方式抗原特異性親和純化
- 標(biāo)記物無(wú)標(biāo)記物
- 免疫原 RPB967Hu02-載脂蛋白A4(APOA4)重組蛋白
- 緩沖液成份0.01M 磷酸鹽緩沖液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
- 性狀液體
- 濃度0.5mg/mL
- 且適物種-
- 應(yīng)用WB; IHC
如果抗體需用于流式細(xì)胞術(shù)，請(qǐng)參見(jiàn)流式抗體。 - 下載 英文說(shuō)明書 中文說(shuō)明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價(jià)格 ¥ 299 ¥ 697 ¥ 996 ¥ 2490 ¥ 9960
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
DAB staining on IHC-P; Samples: Human Liver Tissue; Primary Ab: 20μg/ml Rabbit Anti-Human APOA4 Antibody Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody (Catalog: SAA544Rb19)
-
DAB staining on IHC-P;
Samples: Human Small intestine Tissue;
Primary Ab: 20μg/ml Rabbit Anti-Human APOA4 Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19)
-
Figure. Western Blot; Sample: Recombinant APOA4, Human.
-
Western Blot; Sample: Human Serum;
Primary Ab: 3μg/ml Rabbit Anti-Human APOA4 Antibody
Second Ab: 0.2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19)
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
該抗體是針對(duì)APOA4的兔多克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識(shí)別APOA4。
用法
Western blotting: 0.01-3μg/mL
Immunohistochemistry: 5-30μg/mL
Immunocytochemistry: 5-30μg/mL
Optimal working dilutions must be determined by end user.
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過(guò)兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
抗體標(biāo)記定制服務(wù)
Protein-A/G純化柱
細(xì)胞和組織染色液
抗體陽(yáng)性對(duì)照品
組織/切片定制服務(wù)
磷酸化抗體定制服務(wù)
免疫印跡(WB)實(shí)驗(yàn)服務(wù)
免疫組織化學(xué)(IHC)實(shí)驗(yàn)服務(wù)
免疫細(xì)胞化學(xué)(ICC)實(shí)驗(yàn)服務(wù)
流式細(xì)胞術(shù)(FCM)實(shí)驗(yàn)服務(wù)
免疫沉淀(IP)實(shí)驗(yàn)服務(wù)
免疫熒光(IF)實(shí)驗(yàn)服務(wù)
緩沖液
DAB顯色試劑盒
SABC試劑盒
長(zhǎng)臂生物素標(biāo)記試劑盒
實(shí)時(shí)熒光定量PCR實(shí)驗(yàn)服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| UAPB967Hu02 | 載脂蛋白A4(APOA4)活性蛋白 | Cell?culture;?Activity?Assays. |
| URPB967Hu02 | 載脂蛋白A4(APOA4)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPB967Hu01 | 載脂蛋白A4(APOA4)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAB967Hu01 | 載脂蛋白A4(APOA4)多克隆抗體 | WB; IHC |
| UPAB967Hu02 | 載脂蛋白A4(APOA4)多克隆抗體 | WB; IHC |
| UMAB967Hu21 | 載脂蛋白A4(APOA4)單克隆抗體 | WB |
| UMAB967Hu22 | 載脂蛋白A4(APOA4)單克隆抗體 | WB |
| UMAB967Hu23 | 載脂蛋白A4(APOA4)單克隆抗體 | WB |
| USEB967Hu | 載脂蛋白A4(APOA4)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| USCB967Hu | 載脂蛋白A4(APOA4)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| ULMB967Hu | 載脂蛋白A4(APOA4)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| UKSB967Hu01 | 載脂蛋白A4(APOA4)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Biochimica et Biophysica Acta | Hepatic lipase- and endothelial lipase-deficiency in mice promotes macrophage-to-feces RCT and HDL antioxidant properties [PubMed: 23328279 ] |
| Exp Ther Med. | Differential plasma proteome analysis in patients with high?altitude pulmonary edema at the acute and recovery phases [Pubmed:24940404] |
| EuPA Open Proteomics | Human maternal plasma proteomic changes with parturition [Sciencedirect:S2212968514000506] |
| BJOG | Development of concise audit standards for unplanned return to theate following gynaecological surgery at Gloucestershire Royal Hospital [Doi: 10.1111] |
| Diagnostics | Systemic Alterations of Immune Response-Related Proteins during Glaucoma Development in the Murine Model DBA/2J [Pubmed: 32585848] |
| VETERINARY PATHOLOGY | Pathology and Proteomics-Based Diagnosis of Localized Light-Chain Amyloidosis in Dogs and Cats [Pubmed: 32880234] |
| Cancer Cell Int | Discovery and validation of FBLN1 and ANT3 as potential biomarkers for early detection of cervical cancer [33602229] |
